L
lecanumab
Productby Eisai and Biogen
Heard in 4 episodes across 4 shows since Aug 2026
Lecanemab is an anti-amyloid monoclonal antibody approved for eligible people with early Alzheimer's disease to reduce brain amyloid and modestly slow clinical decline.
Episodes
4
across 4 shows
First heard
Aug 2026
Episodes per month
Public PodLume episodes featuring it, over the last year.
1
2
1
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 1 |
| Sep 2026 | 2 |
| Oct 2026 | 1 |
| Nov 2026 | 0 |
Email alert
Email me when lecanumab comes up on a podcast
One email a week at most, with the new episodes that mention lecanumab. Free, no account needed, unsubscribe in one click.
Episodes
4 episodes featuring lecanumab, newest first
- Oct 19, 2026
Alzheimer’s progress arrives with serious caveatsUnexplainableOct 19, 2026 - Sep 21, 2026
Alzheimer’s care weighs earlier diagnosis against treatment riskThe Curbsiders Internal Medicine PodcastSep 21, 2026 - Sep 16, 2026
Alzheimer’s drugs offer progress after decades of disappointmentToday, ExplainedSep 16, 2026 - Aug 20, 2026
Brain inflammation may be a metabolic problem in disguiseExtend Podcast with Darshan Shah, MDAug 20, 2026